Eric Topol @EricTopol · 02 Sep 2026
The newly approved, hit drug vs pancreatic cancer (daraxonrasib) also clicked in a Phase 1/2 clinical trial with some efficacy for patients with previously treated non-small-cell lung cancer and RAS mutations @NEJM https://t.co/h4rANahAqs https://t.co/lyb5XxXYQq
24 000Views
139Likes
30Reposts
6Replies
4Quotes
21Bookmarks
Is that a lot?
0.90×vs this author's median26 758 views is typical
25Percentile for this authorof 4 recent posts
1.08×vs 100K–1M median22 159 views is typical
2.92%Reachviews ÷ followers
0.75%Engagement rateof viewers reacted